Spotlight on Radiology
Interstitial Lung Disease Forum 2021: A Look at the Latest Evidence and Future Perspectives—Session 1
StartActivity Details
ABIM MOC Credit/AANP Credit
Expires: March 30, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, rheumatologists, internists, radiologists, nurse practitioners, physician assistants and other health care professionals involved in the management of patients with interstitial lung disease (ILD).
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Apply the latest technologies and guidelines to the timely recognition of patients with ILD as well as the accurate determination of subtype.
- Apply knowledge of the latest long-term and real-world evidence to the early and sustained treatment of patients with IPF.
- Assess the latest clinical evidence regarding the treatment of patients with ILD.
Activity Description
Interstitial lung disease (ILD) encompasses a large group of pulmonary conditions characterized by tissue scarring, or fibrosis. Lung damage associated with ILD is often irreversible and may be progressive. Various causes have been identified, including long-term exposure to hazardous materials (e.g., asbestos); bacterial, viral, and fungal infections; and autoimmune connective tissue diseases affecting the lung. In some cases, the underlying cause remains unidentified. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, but there is a large and diverse group of patients who develop a progressive fibrosing phenotype of ILD (PF-ILD) who do not meet IPF diagnostic criteria but have a similar natural history and prognosis. Historically, treatment options for ILD have been limited, but new agents and indications have been approved in recent years. It is critical that pulmonologists, rheumatologists, and other providers who care for patients with ILD are aware of the latest clinical evidence on optimal treatment approaches for various ILD subtypes. In this two-part educational series including clinical cases, expert clinicians will discuss the latest evidence-based approaches to diagnosis, classification, and management of patients with ILD. Faculty also will review clinical trial and real-world data to support optimal treatment and improved outcomes for patients with ILD.
Agenda
Introduction
Steven D. Nathan, MD
Understanding IPF and Non-IPF ILDs: What’s New in Diagnosis
and Classification
Lisa H. Lancaster, MD
Long-Term and Real-World Studies in IPF – What Can We
Learn?
Robert J. Kaner, MD
Clinical Cases
Lisa H. Lancaster, MD, and Robert J. Kaner, MD
Activity Chair
Medical Director
Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Falls Church, VA
Disclosures:
Consulting Fee: Altavant, Bellerophon, Boehringer Ingelheim, Galapagos, Roche/Genentech, United Therapeutics
Speakers Bureau: Boehringer Ingelheim, Roche/Genentech
Faculty
Associate Professor of Clinical Medicine
Associate Professor of Genetic Medicine
Weill Cornell Medicine
New York, NY
Disclosures:
Consulting Fee: Boehringer Ingelheim, Galapagos, Genentech, Pliant, PureTech, United Therapeutics
Speakers Bureau: Genentech
Contracted Research: Bellerophon, Boehringer Ingelheim, Respivant, Toray
Associate Professor
Division of Allergy, Pulmonary, and Critical Care Medicine
Director, Vanderbilt Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN
Disclosures:
Spouse: Medtronic
Consulting Fee: AstraZeneca, DevPro Biopharma, Galapagos, Genentech, United Therapeutics, Veracyte
Speakers Bureau: Boehringer Ingelheim, Genentech
Contracted Research: Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, FibroGen, Galapagos, Galecto, Novartis, Pliant, Respivant
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure:
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure:
No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 1.25 Medical Knowledge MOC points in
the American Board of Internal Medicine's (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider's responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
This activity is approved for 1.25 contact hour(s) of continuing education (which includes 0.58 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 21034784. This activity was planned in accordance with AANP Accreditation Standards and Policies.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.
Statement of Commercial Support
This activity is supported by educational grants from Genentech, Inc. and Veracyte, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
ABIM MOC Credit/AANP Credit
Expires: March 30, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, rheumatologists, internists, radiologists, nurse practitioners, physician assistants and other health care professionals involved in the management of patients with interstitial lung disease (ILD).
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Apply the latest technologies and guidelines to the timely recognition of patients with ILD as well as the accurate determination of subtype.
- Apply knowledge of the latest long-term and real-world evidence to the early and sustained treatment of patients with IPF.
- Assess the latest clinical evidence regarding the treatment of patients with ILD.
Activity Description
Interstitial lung disease (ILD) encompasses a large group of pulmonary conditions characterized by tissue scarring, or fibrosis. Lung damage associated with ILD is often irreversible and may be progressive. Various causes have been identified, including long-term exposure to hazardous materials (e.g., asbestos); bacterial, viral, and fungal infections; and autoimmune connective tissue diseases affecting the lung. In some cases, the underlying cause remains unidentified. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, but there is a large and diverse group of patients who develop a progressive fibrosing phenotype of ILD (PF-ILD) who do not meet IPF diagnostic criteria but have a similar natural history and prognosis. Historically, treatment options for ILD have been limited, but new agents and indications have been approved in recent years. It is critical that pulmonologists, rheumatologists, and other providers who care for patients with ILD are aware of the latest clinical evidence on optimal treatment approaches for various ILD subtypes. In this two-part educational series including clinical cases, expert clinicians will discuss the latest evidence-based approaches to diagnosis, classification, and management of patients with ILD. Faculty also will review clinical trial and real-world data to support optimal treatment and improved outcomes for patients with ILD.
Agenda
Introduction
Steven D. Nathan, MD
Understanding IPF and Non-IPF ILDs: What’s New in Diagnosis
and Classification
Lisa H. Lancaster, MD
Long-Term and Real-World Studies in IPF – What Can We
Learn?
Robert J. Kaner, MD
Clinical Cases
Lisa H. Lancaster, MD, and Robert J. Kaner, MD
Activity Chair
Medical Director
Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Falls Church, VA
Disclosures:
Consulting Fee: Altavant, Bellerophon, Boehringer Ingelheim, Galapagos, Roche/Genentech, United Therapeutics
Speakers Bureau: Boehringer Ingelheim, Roche/Genentech
Faculty
Associate Professor of Clinical Medicine
Associate Professor of Genetic Medicine
Weill Cornell Medicine
New York, NY
Disclosures:
Consulting Fee: Boehringer Ingelheim, Galapagos, Genentech, Pliant, PureTech, United Therapeutics
Speakers Bureau: Genentech
Contracted Research: Bellerophon, Boehringer Ingelheim, Respivant, Toray
Associate Professor
Division of Allergy, Pulmonary, and Critical Care Medicine
Director, Vanderbilt Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN
Disclosures:
Spouse: Medtronic
Consulting Fee: AstraZeneca, DevPro Biopharma, Galapagos, Genentech, United Therapeutics, Veracyte
Speakers Bureau: Boehringer Ingelheim, Genentech
Contracted Research: Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, FibroGen, Galapagos, Galecto, Novartis, Pliant, Respivant
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure:
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure:
No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 1.25 Medical Knowledge MOC points in
the American Board of Internal Medicine's (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider's responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
This activity is approved for 1.25 contact hour(s) of continuing education (which includes 0.58 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 21034784. This activity was planned in accordance with AANP Accreditation Standards and Policies.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.
Statement of Commercial Support
This activity is supported by educational grants from Genentech, Inc. and Veracyte, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Radiology Presentations
Interstitial Lung Disease Forum 2021: A Look at the Latest Evidence and Future Perspectives—Session 1
StartActivity Details
ABIM MOC Credit/AANP Credit
Expires: March 30, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, rheumatologists, internists, radiologists, nurse practitioners, physician assistants and other health care professionals involved in the management of patients with interstitial lung disease (ILD).
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Apply the latest technologies and guidelines to the timely recognition of patients with ILD as well as the accurate determination of subtype.
- Apply knowledge of the latest long-term and real-world evidence to the early and sustained treatment of patients with IPF.
- Assess the latest clinical evidence regarding the treatment of patients with ILD.
Activity Description
Interstitial lung disease (ILD) encompasses a large group of pulmonary conditions characterized by tissue scarring, or fibrosis. Lung damage associated with ILD is often irreversible and may be progressive. Various causes have been identified, including long-term exposure to hazardous materials (e.g., asbestos); bacterial, viral, and fungal infections; and autoimmune connective tissue diseases affecting the lung. In some cases, the underlying cause remains unidentified. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, but there is a large and diverse group of patients who develop a progressive fibrosing phenotype of ILD (PF-ILD) who do not meet IPF diagnostic criteria but have a similar natural history and prognosis. Historically, treatment options for ILD have been limited, but new agents and indications have been approved in recent years. It is critical that pulmonologists, rheumatologists, and other providers who care for patients with ILD are aware of the latest clinical evidence on optimal treatment approaches for various ILD subtypes. In this two-part educational series including clinical cases, expert clinicians will discuss the latest evidence-based approaches to diagnosis, classification, and management of patients with ILD. Faculty also will review clinical trial and real-world data to support optimal treatment and improved outcomes for patients with ILD.
Agenda
Introduction
Steven D. Nathan, MD
Understanding IPF and Non-IPF ILDs: What’s New in Diagnosis
and Classification
Lisa H. Lancaster, MD
Long-Term and Real-World Studies in IPF – What Can We
Learn?
Robert J. Kaner, MD
Clinical Cases
Lisa H. Lancaster, MD, and Robert J. Kaner, MD
Activity Chair
Medical Director
Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Falls Church, VA
Disclosures:
Consulting Fee: Altavant, Bellerophon, Boehringer Ingelheim, Galapagos, Roche/Genentech, United Therapeutics
Speakers Bureau: Boehringer Ingelheim, Roche/Genentech
Faculty
Associate Professor of Clinical Medicine
Associate Professor of Genetic Medicine
Weill Cornell Medicine
New York, NY
Disclosures:
Consulting Fee: Boehringer Ingelheim, Galapagos, Genentech, Pliant, PureTech, United Therapeutics
Speakers Bureau: Genentech
Contracted Research: Bellerophon, Boehringer Ingelheim, Respivant, Toray
Associate Professor
Division of Allergy, Pulmonary, and Critical Care Medicine
Director, Vanderbilt Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN
Disclosures:
Spouse: Medtronic
Consulting Fee: AstraZeneca, DevPro Biopharma, Galapagos, Genentech, United Therapeutics, Veracyte
Speakers Bureau: Boehringer Ingelheim, Genentech
Contracted Research: Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, FibroGen, Galapagos, Galecto, Novartis, Pliant, Respivant
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure:
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure:
No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 1.25 Medical Knowledge MOC points in
the American Board of Internal Medicine's (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider's responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
This activity is approved for 1.25 contact hour(s) of continuing education (which includes 0.58 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 21034784. This activity was planned in accordance with AANP Accreditation Standards and Policies.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.
Statement of Commercial Support
This activity is supported by educational grants from Genentech, Inc. and Veracyte, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
ABIM MOC Credit/AANP Credit
Expires: March 30, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, rheumatologists, internists, radiologists, nurse practitioners, physician assistants and other health care professionals involved in the management of patients with interstitial lung disease (ILD).
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Apply the latest technologies and guidelines to the timely recognition of patients with ILD as well as the accurate determination of subtype.
- Apply knowledge of the latest long-term and real-world evidence to the early and sustained treatment of patients with IPF.
- Assess the latest clinical evidence regarding the treatment of patients with ILD.
Activity Description
Interstitial lung disease (ILD) encompasses a large group of pulmonary conditions characterized by tissue scarring, or fibrosis. Lung damage associated with ILD is often irreversible and may be progressive. Various causes have been identified, including long-term exposure to hazardous materials (e.g., asbestos); bacterial, viral, and fungal infections; and autoimmune connective tissue diseases affecting the lung. In some cases, the underlying cause remains unidentified. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, but there is a large and diverse group of patients who develop a progressive fibrosing phenotype of ILD (PF-ILD) who do not meet IPF diagnostic criteria but have a similar natural history and prognosis. Historically, treatment options for ILD have been limited, but new agents and indications have been approved in recent years. It is critical that pulmonologists, rheumatologists, and other providers who care for patients with ILD are aware of the latest clinical evidence on optimal treatment approaches for various ILD subtypes. In this two-part educational series including clinical cases, expert clinicians will discuss the latest evidence-based approaches to diagnosis, classification, and management of patients with ILD. Faculty also will review clinical trial and real-world data to support optimal treatment and improved outcomes for patients with ILD.
Agenda
Introduction
Steven D. Nathan, MD
Understanding IPF and Non-IPF ILDs: What’s New in Diagnosis
and Classification
Lisa H. Lancaster, MD
Long-Term and Real-World Studies in IPF – What Can We
Learn?
Robert J. Kaner, MD
Clinical Cases
Lisa H. Lancaster, MD, and Robert J. Kaner, MD
Activity Chair
Medical Director
Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Falls Church, VA
Disclosures:
Consulting Fee: Altavant, Bellerophon, Boehringer Ingelheim, Galapagos, Roche/Genentech, United Therapeutics
Speakers Bureau: Boehringer Ingelheim, Roche/Genentech
Faculty
Associate Professor of Clinical Medicine
Associate Professor of Genetic Medicine
Weill Cornell Medicine
New York, NY
Disclosures:
Consulting Fee: Boehringer Ingelheim, Galapagos, Genentech, Pliant, PureTech, United Therapeutics
Speakers Bureau: Genentech
Contracted Research: Bellerophon, Boehringer Ingelheim, Respivant, Toray
Associate Professor
Division of Allergy, Pulmonary, and Critical Care Medicine
Director, Vanderbilt Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN
Disclosures:
Spouse: Medtronic
Consulting Fee: AstraZeneca, DevPro Biopharma, Galapagos, Genentech, United Therapeutics, Veracyte
Speakers Bureau: Boehringer Ingelheim, Genentech
Contracted Research: Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, FibroGen, Galapagos, Galecto, Novartis, Pliant, Respivant
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure:
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure:
No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 1.25 Medical Knowledge MOC points in
the American Board of Internal Medicine's (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider's responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
This activity is approved for 1.25 contact hour(s) of continuing education (which includes 0.58 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 21034784. This activity was planned in accordance with AANP Accreditation Standards and Policies.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.
Statement of Commercial Support
This activity is supported by educational grants from Genentech, Inc. and Veracyte, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Interstitial Lung Disease Forum 2021: A Look at the Latest Evidence and Future Perspectives—Session 2
StartActivity Details
ABIM MOC Credit/AANP Credit
Expires: March 30, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, rheumatologists, internists, radiologists, nurse practitioners, physician assistants and other health care professionals involved in the management of patients with interstitial lung disease (ILD).
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Assess the latest clinical evidence regarding the treatment of patients with ILD.
- Identify patients with worsening progressive fibrosing ILD who may benefit from new treatment options.
- Utilize a multidisciplinary care team, including the patient, to optimize outcomes for patients with ILD.
Activity Description
Interstitial lung disease (ILD) encompasses a large group of pulmonary conditions characterized by tissue scarring, or fibrosis. Lung damage associated with ILD is often irreversible and may be progressive. Various causes have been identified, including long-term exposure to hazardous materials (e.g., asbestos); bacterial, viral, and fungal infections; and autoimmune connective tissue diseases affecting the lung. In some cases, the underlying cause remains unidentified. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, but there is a large and diverse group of patients who develop a progressive fibrosing phenotype of ILD (PF-ILD) who do not meet IPF diagnostic criteria but have a similar natural history and prognosis. Historically, treatment options for ILD have been limited, but new agents and indications have been approved in recent years. It is critical that pulmonologists, rheumatologists, and other providers who care for patients with ILD are aware of the latest clinical evidence on optimal treatment approaches for various ILD subtypes. In this two-part educational series including clinical cases, expert clinicians will discuss the latest evidence-based approaches to diagnosis, classification, and management of patients with ILD. Faculty also will review clinical trial and real-world data to support optimal treatment and improved outcomes for patients with ILD.
Agenda
Introduction
Steven D. Nathan, MD
Updates in Non-IPF ILD
Kevin R. Flaherty, MD, MS
Clinical Cases
Amy L. Olson, MD, MSPH
Current Challenges and Future Directions in ILD and
IPF
Steven D. Nathan, MD
Activity Chair
Medical Director
Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Falls Church, VA
Disclosures:
Consulting Fee: Altavant, Bellerophon, Boehringer Ingelheim, Galapagos, Roche/Genentech, United Therapeutics
Speakers Bureau: Boehringer Ingelheim, Roche/Genentech
Faculty
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI
Disclosures:
Consulting Fee: Bellerophon, Blade Therapeutics, Boehringer Ingelheim, Respivant Sciences, Roche/Genentech, Shionogi, United Therapeutics
Contracted Research: Boehringer Ingelheim
Associate Professor
Department of Medicine
Medical Director
Pulmonary Physiology Unit
National Jewish Health
Denver, CO
Disclosures:
Consulting Fee: MGC Diagnostics
Speakers Bureau: Boehringer Ingelheim, Genentech
Contracted Research: United Therapeutics
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure:
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure:
No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 1.25 Medical Knowledge MOC points in
the American Board of Internal Medicine's (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider's responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
This activity is approved for 1.25 contact hour(s) of continuing education (which includes 0.67 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 21034785. This activity was planned in accordance with AANP Accreditation Standards and Policies.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.
Statement of Commercial Support
This activity is supported by educational grants from Genentech, Inc. and Veracyte, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
ABIM MOC Credit/AANP Credit
Expires: March 30, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, rheumatologists, internists, radiologists, nurse practitioners, physician assistants and other health care professionals involved in the management of patients with interstitial lung disease (ILD).
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Assess the latest clinical evidence regarding the treatment of patients with ILD.
- Identify patients with worsening progressive fibrosing ILD who may benefit from new treatment options.
- Utilize a multidisciplinary care team, including the patient, to optimize outcomes for patients with ILD.
Activity Description
Interstitial lung disease (ILD) encompasses a large group of pulmonary conditions characterized by tissue scarring, or fibrosis. Lung damage associated with ILD is often irreversible and may be progressive. Various causes have been identified, including long-term exposure to hazardous materials (e.g., asbestos); bacterial, viral, and fungal infections; and autoimmune connective tissue diseases affecting the lung. In some cases, the underlying cause remains unidentified. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, but there is a large and diverse group of patients who develop a progressive fibrosing phenotype of ILD (PF-ILD) who do not meet IPF diagnostic criteria but have a similar natural history and prognosis. Historically, treatment options for ILD have been limited, but new agents and indications have been approved in recent years. It is critical that pulmonologists, rheumatologists, and other providers who care for patients with ILD are aware of the latest clinical evidence on optimal treatment approaches for various ILD subtypes. In this two-part educational series including clinical cases, expert clinicians will discuss the latest evidence-based approaches to diagnosis, classification, and management of patients with ILD. Faculty also will review clinical trial and real-world data to support optimal treatment and improved outcomes for patients with ILD.
Agenda
Introduction
Steven D. Nathan, MD
Updates in Non-IPF ILD
Kevin R. Flaherty, MD, MS
Clinical Cases
Amy L. Olson, MD, MSPH
Current Challenges and Future Directions in ILD and
IPF
Steven D. Nathan, MD
Activity Chair
Medical Director
Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Falls Church, VA
Disclosures:
Consulting Fee: Altavant, Bellerophon, Boehringer Ingelheim, Galapagos, Roche/Genentech, United Therapeutics
Speakers Bureau: Boehringer Ingelheim, Roche/Genentech
Faculty
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI
Disclosures:
Consulting Fee: Bellerophon, Blade Therapeutics, Boehringer Ingelheim, Respivant Sciences, Roche/Genentech, Shionogi, United Therapeutics
Contracted Research: Boehringer Ingelheim
Associate Professor
Department of Medicine
Medical Director
Pulmonary Physiology Unit
National Jewish Health
Denver, CO
Disclosures:
Consulting Fee: MGC Diagnostics
Speakers Bureau: Boehringer Ingelheim, Genentech
Contracted Research: United Therapeutics
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure:
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure:
No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 1.25 Medical Knowledge MOC points in
the American Board of Internal Medicine's (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider's responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
This activity is approved for 1.25 contact hour(s) of continuing education (which includes 0.67 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 21034785. This activity was planned in accordance with AANP Accreditation Standards and Policies.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.
Statement of Commercial Support
This activity is supported by educational grants from Genentech, Inc. and Veracyte, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
What Have We Learned? The Neverending Story of COVID-19 and ILD
StartActivity Details
Expires: December 10, 2021
Accredited By
Target Audience
This activity is intended for pulmonologists, pathologists, radiologists, infectious disease specialists, primary care physicians, and other healthcare providers who care for patients with COVID-19.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Describe the presentation and impact of COVID-19 infection in patients with progressive pulmonary fibrosis
- Implement strategies to best manage patients with both COVID-19 infection and progressive CF-ILD
- Incorporate recommendations to appropriately monitor patients with COVID-19-related acute lung injury or ARDS
Activity Description
What have we learned about COVID-19 and interstitial lung disease (ILD)? What do we know now about the potential for fibrosis in those who develop severe COVID-19? This 30-minute “Hot Topics” CME activity, featuring leading pulmonology expert Tanzira Zaman, MD, will break down the key insights as well as the latest trial data and recommendations. This activity will feature text and charts with interspersed short video snippets. Dive into this ever-engaging story and learn more!
Statement of Educational Need
Patients with CF-ILD are, unfortunately, a significantly high-risk group for mortality with COVID-19. Therefore, optimal awareness of both COVID-19 and ILD management is essential. After completing this activity, clinician learners will be better able to evaluate for comorbid COVID-19 infection and ILD, as well as improve the care and management of patients who present with both of these conditions.
Faculty
Director, Interstitial Lung Disease Program
Associate Program Director, Pulmonary & Critical Care Fellowship
Division of Pulmonary & Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, CA
Conflict of Interest Policy/Disclosure Statement
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Tanzira Zaman, MD
Advisory Panel: United Therapeutics Corporation
Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc.
Discussion of off-label, Investigational, or Experimental Drug/Device Use: dexamethasone and other treatments not yet approved to treat COVID-19.
As of October 22, 2020, remdesivir is now approved for COVID-19 treatment.
As of November 9, 2020, the FDA has also issued an EUA for bamlanivimab for mild-to-moderate COVID-19 in adult and pediatric patients.
Staff Disclosure
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Accreditation Statement
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)
Instructions for Receiving Credit
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Statement of Commercial Support
Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Contact Information for Questions About the Activity
For questions, contact Michelle Forcier at mforcier@achlcme.org
Activity Details
Expires: December 10, 2021
Accredited By
Target Audience
This activity is intended for pulmonologists, pathologists, radiologists, infectious disease specialists, primary care physicians, and other healthcare providers who care for patients with COVID-19.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Describe the presentation and impact of COVID-19 infection in patients with progressive pulmonary fibrosis
- Implement strategies to best manage patients with both COVID-19 infection and progressive CF-ILD
- Incorporate recommendations to appropriately monitor patients with COVID-19-related acute lung injury or ARDS
Activity Description
What have we learned about COVID-19 and interstitial lung disease (ILD)? What do we know now about the potential for fibrosis in those who develop severe COVID-19? This 30-minute “Hot Topics” CME activity, featuring leading pulmonology expert Tanzira Zaman, MD, will break down the key insights as well as the latest trial data and recommendations. This activity will feature text and charts with interspersed short video snippets. Dive into this ever-engaging story and learn more!
Statement of Educational Need
Patients with CF-ILD are, unfortunately, a significantly high-risk group for mortality with COVID-19. Therefore, optimal awareness of both COVID-19 and ILD management is essential. After completing this activity, clinician learners will be better able to evaluate for comorbid COVID-19 infection and ILD, as well as improve the care and management of patients who present with both of these conditions.
Faculty
Director, Interstitial Lung Disease Program
Associate Program Director, Pulmonary & Critical Care Fellowship
Division of Pulmonary & Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, CA
Conflict of Interest Policy/Disclosure Statement
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Tanzira Zaman, MD
Advisory Panel: United Therapeutics Corporation
Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc.
Discussion of off-label, Investigational, or Experimental Drug/Device Use: dexamethasone and other treatments not yet approved to treat COVID-19.
As of October 22, 2020, remdesivir is now approved for COVID-19 treatment.
As of November 9, 2020, the FDA has also issued an EUA for bamlanivimab for mild-to-moderate COVID-19 in adult and pediatric patients.
Staff Disclosure
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Accreditation Statement
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)
Instructions for Receiving Credit
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Statement of Commercial Support
Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Contact Information for Questions About the Activity
For questions, contact Michelle Forcier at mforcier@achlcme.org
New Choices in Targeted Treatments for Advanced or Metastatic Urothelial Carcinoma: Plot Your Own Course
StartActivity Details
Expires: November 23, 2021
Accredited By
Target Audience
This educational initiative has been designed for genitourinary oncologists, medical oncologists, surgical oncologists, radiologists, urologists, nurse practitioners (NPs), physician assistants (PAs), clinical nurse specialists (CNSs), advanced practice nurses (APNs), oncology clinical nurses (OCNs), and clinical oncology pharmacists (BCOPs) involved in the care and coordination of patients with urothelial carcinoma (UC).
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of UC
- Outline efficacy and safety findings from key clinical trials of approved and investigational novel treatments developed for the treatment of advanced or metastatic UC (mUC)
Statement of Educational Need
In advanced or metastatic urothelial carcinoma (UC) a heavily cytotoxic “sledgehammer” approach has traditionally been used. Platinum-based chemotherapy is still the preferred first-line approach. But this non-specific cytotoxic treatment is often intolerable for the typically older UC patient.
Until recently, there were no second-line options beyond the chemotherapeutic sledgehammer. Today, treatments with more selective mechanisms of action take advantage of fresh translational insights into UC.
These novel therapeutics offer more efficient targeting for patients who have run out of options. But for clinicians, the introduction of these agents complicates an already complex condition. This activity will guide them in selecting and using these options.
In this case-based activity you will navigate a simulated patient case, making clinical decisions when prompted. Feedback regarding your decisions will be provided as you move through the case.
Co-Chairs
Professor, Centre of Experimental Cancer Medicines
Bart’s Cancer Institute
St. Bartholomew’s Hospital
London, United Kingdom
Chief of Clinical Trials
Department of Hematology/Oncology
Vanderbilt University Medical Center
Nashville, Tennessee
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education, Inc requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Thomas Powell, MD:
Consulting Fees: AstraZeneca, Bristol Myers Squibb, Exelixis,
Incyte, Ipsen, Merck/Merck Sharp & Dohme, Novartis, Pfizer, Seattle
Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, and
Roche
Contracted Research: AstraZeneca, Roche, Bristol Myers
Squibb, Exelixis, Ipsen, Merck/Merck Sharp & Dohme, Novartis, Pfizer,
Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, and
Eisai
Other: Expenses/Travel/Accommodation: Roche, Pfizer, Merck
Sharp & Dohme, AstraZeneca, and Ipsen
Brian Rini, MD:
Consulting Fees: Merck, Pfizer, Bristol Myers Squibb, Aravive, AVEO
Pharmaceuticals, GlaxoSmithKline
Contracted Research: Merck, Bristol Myers Squibb, Exelixis,
Pfizer, AstraZeneca
Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
Integrity Continuing Education, Inc is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.
Designation of Credit
Integrity Continuing Education, Inc designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of November 23, 2020 through November 23, 2021, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc., EMD, Serono, Inc., and Pfizer, Inc. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.
Statement of Commercial Support
Supported by an educational grant from EMD Serono, Inc. and Pfizer, Inc.
Activity Details
Expires: November 23, 2021
Accredited By
Target Audience
This educational initiative has been designed for genitourinary oncologists, medical oncologists, surgical oncologists, radiologists, urologists, nurse practitioners (NPs), physician assistants (PAs), clinical nurse specialists (CNSs), advanced practice nurses (APNs), oncology clinical nurses (OCNs), and clinical oncology pharmacists (BCOPs) involved in the care and coordination of patients with urothelial carcinoma (UC).
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of UC
- Outline efficacy and safety findings from key clinical trials of approved and investigational novel treatments developed for the treatment of advanced or metastatic UC (mUC)
Statement of Educational Need
In advanced or metastatic urothelial carcinoma (UC) a heavily cytotoxic “sledgehammer” approach has traditionally been used. Platinum-based chemotherapy is still the preferred first-line approach. But this non-specific cytotoxic treatment is often intolerable for the typically older UC patient.
Until recently, there were no second-line options beyond the chemotherapeutic sledgehammer. Today, treatments with more selective mechanisms of action take advantage of fresh translational insights into UC.
These novel therapeutics offer more efficient targeting for patients who have run out of options. But for clinicians, the introduction of these agents complicates an already complex condition. This activity will guide them in selecting and using these options.
In this case-based activity you will navigate a simulated patient case, making clinical decisions when prompted. Feedback regarding your decisions will be provided as you move through the case.
Co-Chairs
Professor, Centre of Experimental Cancer Medicines
Bart’s Cancer Institute
St. Bartholomew’s Hospital
London, United Kingdom
Chief of Clinical Trials
Department of Hematology/Oncology
Vanderbilt University Medical Center
Nashville, Tennessee
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education, Inc requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Thomas Powell, MD:
Consulting Fees: AstraZeneca, Bristol Myers Squibb, Exelixis,
Incyte, Ipsen, Merck/Merck Sharp & Dohme, Novartis, Pfizer, Seattle
Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, and
Roche
Contracted Research: AstraZeneca, Roche, Bristol Myers
Squibb, Exelixis, Ipsen, Merck/Merck Sharp & Dohme, Novartis, Pfizer,
Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, and
Eisai
Other: Expenses/Travel/Accommodation: Roche, Pfizer, Merck
Sharp & Dohme, AstraZeneca, and Ipsen
Brian Rini, MD:
Consulting Fees: Merck, Pfizer, Bristol Myers Squibb, Aravive, AVEO
Pharmaceuticals, GlaxoSmithKline
Contracted Research: Merck, Bristol Myers Squibb, Exelixis,
Pfizer, AstraZeneca
Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
Integrity Continuing Education, Inc is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.
Designation of Credit
Integrity Continuing Education, Inc designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of November 23, 2020 through November 23, 2021, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc., EMD, Serono, Inc., and Pfizer, Inc. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.
Statement of Commercial Support
Supported by an educational grant from EMD Serono, Inc. and Pfizer, Inc.
The Clinical Significance of Imaging in the Management of ADPKD
StartActivity Details
Expires: May 26, 2021
Target Audience
This activity has been designed to meet the educational needs of radiologists and other health care professionals involved in the diagnosis, treatment and management of patients with autosomal dominant polycystic kidney disease (ADPKD).
Overview
This Expert Exchange webcast is designed to help clinicians better understand the importance of radiologic imaging in the clinical management of patients affected by ADPKD.
Educational Objectives
Upon completion of this activity, participants will be better able to do the following:
- Recognize the significance of total kidney volume (TKV) in ADPKD
- Summarize the methods for assessing TKV
- Recognize atypical vs. typical presentations of PKD
- Summarize clinical decision-making steps regarding treatment decisions
Faculty
Chief, GU Section
Professor of Radiology
Mayo Clinic
Rochester, MN
Director, PKD Program and CORE Kidney Program
Professor and Clinical Chief, Nephrology
UCLA Geffen School of Medicine
Los Angeles, CA
Financial Support
This activity has been supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.
Providers
Jointly provided by the University of Florida College of Medicine and Novus Medical Education.
Joint Accreditation Statement
This activity has
been planned and implemented in accordance with the accreditation
requirements and policies of the Accreditation Council for Continuing Medical
Education (ACCME) through the joint providership of the University of Florida
College of Medicine and Novus Medical Education. The University of Florida
College of Medicine is accredited by the ACCME to provide continuing medical
education for physicians.
Physician Continuing Medical Education
The University of Florida College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
The University of Florida College of Medicine requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to UF COM policy. UF COM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Faculty
Dr. Kim reports no relevant financial relationships to disclose.
Dr. Rastogi reports the following relevant financial relationships:
- Speakers Bureau/Advisory Board - Genzyme/Sanofi, Otsuka
- Research Support - Kadmon, Reata Pharmaceuticals, Sanofi
Planners and Managers
The UF COM and Novus Medical Education planners and managers have nothing to
disclose.
Method of Participation
There are no fees for participating and receiving CME credit for this activity. To claim credit, participants must complete the following:
- Read the educational objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the pre-test.
- View the webcast.
- Complete the post-test and evaluation.
- Physicians who receive a grade of 80% or better on the post-test and complete the evaluation will receive a CME certificate.
- All other participants who receive a grade of 80% or better on the post-test and complete the evaluation will receive a Certificate of Participation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CME Provider
The University of Florida College of Medicine can be contacted at cme-mail@ufl.edu or 352.733.0064.
Activity Details
Expires: May 26, 2021
Target Audience
This activity has been designed to meet the educational needs of radiologists and other health care professionals involved in the diagnosis, treatment and management of patients with autosomal dominant polycystic kidney disease (ADPKD).
Overview
This Expert Exchange webcast is designed to help clinicians better understand the importance of radiologic imaging in the clinical management of patients affected by ADPKD.
Educational Objectives
Upon completion of this activity, participants will be better able to do the following:
- Recognize the significance of total kidney volume (TKV) in ADPKD
- Summarize the methods for assessing TKV
- Recognize atypical vs. typical presentations of PKD
- Summarize clinical decision-making steps regarding treatment decisions
Faculty
Chief, GU Section
Professor of Radiology
Mayo Clinic
Rochester, MN
Director, PKD Program and CORE Kidney Program
Professor and Clinical Chief, Nephrology
UCLA Geffen School of Medicine
Los Angeles, CA
Financial Support
This activity has been supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.
Providers
Jointly provided by the University of Florida College of Medicine and Novus Medical Education.
Joint Accreditation Statement
This activity has
been planned and implemented in accordance with the accreditation
requirements and policies of the Accreditation Council for Continuing Medical
Education (ACCME) through the joint providership of the University of Florida
College of Medicine and Novus Medical Education. The University of Florida
College of Medicine is accredited by the ACCME to provide continuing medical
education for physicians.
Physician Continuing Medical Education
The University of Florida College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
The University of Florida College of Medicine requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to UF COM policy. UF COM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Faculty
Dr. Kim reports no relevant financial relationships to disclose.
Dr. Rastogi reports the following relevant financial relationships:
- Speakers Bureau/Advisory Board - Genzyme/Sanofi, Otsuka
- Research Support - Kadmon, Reata Pharmaceuticals, Sanofi
Planners and Managers
The UF COM and Novus Medical Education planners and managers have nothing to
disclose.
Method of Participation
There are no fees for participating and receiving CME credit for this activity. To claim credit, participants must complete the following:
- Read the educational objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the pre-test.
- View the webcast.
- Complete the post-test and evaluation.
- Physicians who receive a grade of 80% or better on the post-test and complete the evaluation will receive a CME certificate.
- All other participants who receive a grade of 80% or better on the post-test and complete the evaluation will receive a Certificate of Participation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CME Provider
The University of Florida College of Medicine can be contacted at cme-mail@ufl.edu or 352.733.0064.